Physician profile
Vu D Tran
NPI 1720424286
$1,960.78
in general payments reported to CMS, 2019-2025
18 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $101 · 2021: $231 · 2022: $214 · 2023: $494 · 2024: $480 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $508.65 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Amgen INC. | $308.31 | 2022-2025 | Otezla, Otezla, Repatha |
| Indivior INC. | $209.23 | 2019-2025 | Sublocade |
| Abiomed | $130.14 | 2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $126.77 | 2023-2024 | Lifevest |
| Nestle Healthcare Nutrition INC. | $126.65 | 2022-2023 | |
| Gilead Sciences, INC. | $95.81 | 2021 | |
| Lilly USA, LLC | $86.21 | 2020-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $76.97 | 2023 | Gallant |
| Braeburn INC. | $54.69 | 2025 | Brixadi |
| Glaxosmithkline, LLC. | $51.46 | 2021-2025 | Arexvy, Shingrix |
| Aimmune Therapeutics, INC. | $39.56 | 2024 | |
| Abbvie INC. | $39.06 | 2021 | |
| Scilex Pharmaceuticals INC. | $33.79 | 2023-2024 | Ztlido |
| Janssen Pharmaceuticals, INC | $27.21 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.36 | 2025 | The Cologuard Plus Collection Kit |
| Paratek Pharmaceuticals, INC. | $15.40 | 2025 | Nuzyra |
| Pfizer INC. | $14.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.